A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
EUREKA
Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
1 other identifier
observational
400
6 countries
6
Brief Summary
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Typical duration for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
January 4, 2024
CompletedFirst Posted
Study publicly available on registry
January 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
April 16, 2026
April 1, 2026
2.4 years
January 4, 2024
April 13, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Mortality at 24 months by stage
Mortality at 24 months by stage will be evaluated
24 months from diagnosis
Secondary Outcomes (1)
Rate of hematologic relapse in Complete Response patients at 2 years by MRD status
2 years from diagnosis
Eligibility Criteria
400 patients with AL amyloidosis will be enrolled at diagnosis and evaluated at any of the participating clinical centers.
You may qualify if:
- diagnosis of systemic AL amyloidosis;
- treatment-naïve;
- age ≥18 years;
- ability to understand and willingness to sign an informed consent;
- planned follow-up at participating center.
You may not qualify if:
- non-AL amyloidosis;
- previous treatment for AL amyloidosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672
Heidelberg, Germany
Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100
Pavia, Italy
UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan
Utrecht, Netherlands
Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra
Pamplona, Spain
University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics
Muttenz, Switzerland
Universidad de la Republica Hospital de Clinicas "Dr Manuel Quintela"
Montevideo, Uruguay
Biospecimen
Peripheral blood, bone marrow aspirate, serum, plasma, urine, fat tissue.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
January 4, 2024
First Posted
January 16, 2024
Study Start
January 1, 2024
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
April 16, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share